# A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

Study · id `cardio:ct-nct06168409` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06168409](<https://clinicaltrials.gov/study/NCT06168409>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06168409

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

## Technical summary

Registry record NCT06168409. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-08-17 (actual). Results posted on 2026-08-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 218 participants (enrolled count; ClinicalTrials.gov record NCT06168409, source copy `cardio:ctgov-nct06168409-2026-08-06`, retrieved 2026-10-26)
- Started: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06168409, source copy `cardio:ctgov-nct06168409-2026-08-06`, retrieved 2026-10-26)
- Primary completion: 2025-08-17 (actual) (ClinicalTrials.gov record NCT06168409, source copy `cardio:ctgov-nct06168409-2026-08-06`, retrieved 2026-10-26)
- Completion: 2025-08-17 (actual) (ClinicalTrials.gov record NCT06168409, source copy `cardio:ctgov-nct06168409-2026-08-06`, retrieved 2026-10-26)
- Results first posted: 2026-08-06 (ClinicalTrials.gov record NCT06168409, source copy `cardio:ctgov-nct06168409-2026-08-06`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Bulgaria; Canada; Czechia; Germany; Greece; Hungary; Malaysia; Philippines; Poland; Saudi Arabia; Slovakia; South Africa; Spain; Taiwan; Thailand; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06168409, source copy `cardio:ctgov-nct06168409-2026-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06168409-2026-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
- Acronym: Bax24
- Condition: Resistant Hypertension
- Intervention (Drug): Baxdrostat
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Resistant hypertension (`cardio:resistant-hypertension`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial (`cardio:pubmed-41794437`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f118642c112c4bdd1d2441defcbea2fe4b26d4fc3dda9088690de1de0d3f24ff
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
